Report Overview

The Indian Pancreatic Cancer Therapeutics market size stood at around USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.

India will witness more than 17.3 lakhs new cases of cancer and more than 8.8 lakh Indians would die because of it. Digitisation in cancer care and treatment is a positive step which has been initialised by some of the leading cancer hospitals of India. A digital centre is being set up to connect all 108 hospitals that are a part of Indias National Cancer Grid. In India, pancreas ranks large numbers of untreatable cancers primarily because of a dearth of funds, knowledge about the disease and extremely poor treatment facilities. As a country, India has a minimal rate of public expenditure (1.5 per centof its GDP) on healthcare which is the cause of the rising incidence of various incurable illnesses, making it a nation with the poorest amount of expenses on public health care.High prevalence of smoking, alcoholism, and obesity are main factors driving the market growth. Sedentary lifestyle led by patients as well as history of pancreatic can play a major role in the market. Low approvals of drugs are likely to lead to lax regulations for making the availability of medications at an affordable price.



Market Drivers

The increasing prevalence of pancreatic cancer is expected to drive the growth of the pancreatic cancer drugs therapeutics market. India presents rewarding opportunities for the key players operating in the Pancreatic Cancer treatment market, owing to growth in awareness about Pancreatic Cancer treatment and rise in adoption of Pancreatic Cancer treatment products. Moreover, improvement in healthcare infrastructure, rise in number of hospitals equipped with advanced medical facilities, developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare further contribute to the market growth.